UBP-302
Jump to navigation
Jump to search
| Names | |
|---|---|
| IUPAC name
2-{[3-[(2S)-2-amino-2-carboxyethyl]-2,6-dioxo-3,6-dihydropyrimidin-1(2H)-yl]methyl}benzoic acid
| |
| Identifiers | |
3D model (JSmol)
|
|
| ChEMBL | |
| ChemSpider | |
| ECHA InfoCard | 100.210.061 |
PubChem CID
|
|
| |
| |
| Properties | |
| C15H15N3O6 | |
| Molar mass | 333.296 g/mol |
Except where otherwise noted, data are given for materials in their standard state (at 25 °C [77 °F], 100 kPa). | |
| Infobox references | |
UBP-302 is a highly selective kainate receptor antagonist used in the study of many neurological processes. It is active at micromolar concentration within an in vitro preparation and specifically targets the GluR5 subunit of the receptor. This compound was developed at the University of Bristol.[1]
References[edit]
- ^ More, JC; Nistico, R; Dolman, NP; Clarke, VR; Alt, AJ; Ogden, AM; Buelens, FP; Troop, HM; et al. (2004). "Characterisation of UBP296: a novel, potent and selective kainate receptor antagonist". Neuropharmacology. 47 (1): 46–64. doi:10.1016/j.neuropharm.2004.03.005. PMID 15165833.
| This drug article relating to the nervous system is a stub. You can help Wikipedia by expanding it. |